Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers

References

• Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490–499.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Winkler J, Waller C, et al. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplant. 1997;19:529–537.
   PubMed Web of Science ®Google Scholar
• Kurnaz F, Kaynar L. Peripheral blood stem cell mobilization failure. Transfus Apher Sci. 2015;53:3–7.
   PubMed Web of Science ®Google Scholar
• Lemoli RM. New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis. 2012;4:e2012066.
   PubMedGoogle Scholar
• Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28:31–40.
   PubMed Web of Science ®Google Scholar
• Park IH, Kim Y, Kim JS, et al. Transfusion-associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies. Transfus Med. 2008;18:97–103.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Jestice K, Scott MA, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999;23:9–13.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Bertz H, Wäsch R, et al. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. Ann Hematol. 2001;80:201–208.
   PubMed Web of Science ®Google Scholar
• Goker H, Etgul S, Buyukasik Y. Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor. Transfus Apher Sci. 2015;53:23–29.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Herbert KE, Demosthenous L, Wiesner G, et al. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplant. 2014;49:1056–1062.
   PubMed Web of Science ®Google Scholar
• Hundemer M, Engelhardt M, Bruckner T, et al. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. J Clin Apher. 2014;29:299–304.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant. 2011;46:52–58.
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of r stem cell mobilization kinetics ” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization. Transfusion. 2011;51:2175–2182.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Chute JP, Gasparetto C, et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant. 2012;47:1051–1055.
   PubMed Web of Science ®Google Scholar
• D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011;46:356–363.
   PubMed Web of Science ®Google Scholar
• Andreola G, Vanazzi A, Radice D, et al. Who should be really considered as a poor mobilizer in the plerixafor era? Transfus Apher Sci. 2012;47:27–32.
   PubMed Web of Science ®Google Scholar
• Civriz Bozdag S, Tekgunduz E, Altunas F. The current status in hematopoietic stem cell mobilization. J Clin Apher. 2015;30:273–280.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25:977–988.
   PubMed Web of Science ®Google Scholar
• Cashen AF. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today. 2009;45:497–505.
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1095–1102.
   PubMed Web of Science ®Google Scholar
• Nademanee AP, DiPersio JF, Maziarz RT, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant. 2012;18:1564–1572.
   PubMed Web of Science ®Google Scholar
• Russell N, Douglas K, Ho AD, et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013;98:172–178.
   PubMed Web of Science ®Google Scholar
• Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. 2010;45:63–68.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Uberti J, Devine S, et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013;48:777–781.
   PubMed Web of Science ®Google Scholar
• Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher. 2016. [Epub ahead of print]. doi: 10.1002/jca.21496.
   PubMed Web of Science ®Google Scholar
• MacFarland R, Hard ML, Scarborough R, et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant. 2010;16:95–101.
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44:1667–1673.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Bertz H, Afting M, et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol. 1999;17:2160–2172.
   PubMed Web of Science ®Google Scholar
• Afifi S, Adel NG, Devlin S, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant. 2016;51:546–552.
   PubMed Web of Science ®Google Scholar
• Veltri L, Cumpston A, Shillingburg A, et al. Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015;17:1785–1792.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–1629.
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009;11:992–1001.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant. 2009;43:909–917.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011;46:64–69.
   PubMed Web of Science ®Google Scholar
• Chow E, Rao KV, Wood WA, et al. Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization. Biol Blood Marrow Transplant. 2014;20:1064–1068.
   PubMed Web of Science ®Google Scholar
• Farina L, Guidetti A, Spina F, et al. Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy + G-CSF. Bone Marrow Transplant. 2014;49:453–455.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortega I, Querol S, Encuentra M, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant. 2015;50:34–39.
   PubMed Web of Science ®Google Scholar
• Clark RE, Bell J, Clark JO, et al. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Blood Cancer J. 2014;4:e255.
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014;164:113–123.
   PubMed Web of Science ®Google Scholar